Prof Lajos Pusztai speaks to ecancer about the results from the I-SPY 2 trial evaluating durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer.

He explains that the olaparib plus durvalumab arm of the trial posed the question of whether it was possible to improve the PCR by adding these drugs to standard of care chemotherapy.

Prof Pusztai reports that the final predicted PCR was higher in all three HER2 negative groups when olaparib and durvalumab was added.